Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

14
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
14
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

18
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
18
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

16
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
16
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

16
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
16
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

34
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
34
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

29
Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
29

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Application of Artificial Intelligence In Drug-target Interactions Prediction: A Review.

npj biomedical innovations·2026
Same author

Neural Network Optimization Reimagined: Decoupled Techniques for Scratch and Fine-Tuning.

IEEE transactions on pattern analysis and machine intelligence·2026
Same author

Enhancing anticancer peptide discovery: A fusion-centric framework with conditional diffusion for prediction and generation.

PLoS computational biology·2026
Same author

MARINE-Transformer: A General-purpose framework for multivariate ocean time series analysis.

Neural networks : the official journal of the International Neural Network Society·2026
Same author

Cohort profile: The Dutch wound monitor cohort and the Swedish Region Halland Integrated Platform (RHIP) wound cohort.

PloS one·2026
Same author

Adaptive Boosting LLMs for Text Classification.

IEEE transactions on neural networks and learning systems·2026

Related Experiment Video

Updated: Jul 30, 2025

Quantification of Atherosclerosis in Mice
06:59

Quantification of Atherosclerosis in Mice

Published on: June 12, 2019

37.8K

Explainable Graph Neural Networks for Atherosclerotic Cardiovascular Disease.

Jens Lundström1, Atiye Sadat Hashemi1, Prayag Tiwari1

  • 1Center for Applied Intelligent Systems Research in Health, Halmstad University, Sweden.

Studies in Health Technology and Informatics
|May 19, 2023
PubMed
Summary
This summary is machine-generated.

This study explores using Graph Neural Networks (GNNs) to model atherosclerotic cardiovascular disease progression. The research focuses on explainable AI (XAI) to build trust in clinical decision support systems for managing cholesterol levels.

Keywords:
Cardiovascular DiseasesEHRGraph Neural Networks

More Related Videos

Quantitative Analysis and Characterization of Atherosclerotic Lesions in the Murine Aortic Sinus
06:43

Quantitative Analysis and Characterization of Atherosclerotic Lesions in the Murine Aortic Sinus

Published on: December 7, 2013

13.8K
Evidence-based Knowledge Synthesis and Hypothesis Validation: Navigating Biomedical Knowledge Bases via Explainable AI and Agentic Systems
05:47

Evidence-based Knowledge Synthesis and Hypothesis Validation: Navigating Biomedical Knowledge Bases via Explainable AI and Agentic Systems

Published on: June 13, 2025

356

Related Experiment Videos

Last Updated: Jul 30, 2025

Quantification of Atherosclerosis in Mice
06:59

Quantification of Atherosclerosis in Mice

Published on: June 12, 2019

37.8K
Quantitative Analysis and Characterization of Atherosclerotic Lesions in the Murine Aortic Sinus
06:43

Quantitative Analysis and Characterization of Atherosclerotic Lesions in the Murine Aortic Sinus

Published on: December 7, 2013

13.8K
Evidence-based Knowledge Synthesis and Hypothesis Validation: Navigating Biomedical Knowledge Bases via Explainable AI and Agentic Systems
05:47

Evidence-based Knowledge Synthesis and Hypothesis Validation: Navigating Biomedical Knowledge Bases via Explainable AI and Agentic Systems

Published on: June 13, 2025

356

Area of Science:

  • Cardiovascular Medicine
  • Artificial Intelligence
  • Machine Learning

Background:

  • Atherosclerotic cardiovascular disease (ASCVD) progression and treatment understanding is crucial for clinical decision support systems.
  • Trust in these systems requires explainable machine learning models for clinicians, developers, and researchers.
  • Graph Neural Networks (GNNs) are emerging for analyzing longitudinal clinical data.

Purpose of the Study:

  • To utilize GNNs for modeling and predicting atherosclerotic cardiovascular disease progression.
  • To explore explainable AI (XAI) methods for GNNs in this context.
  • To investigate the explainability of GNN models for low-density lipoprotein cholesterol levels in long-term ASCVD.

Main Methods:

  • Employing Graph Neural Networks (GNNs) to analyze longitudinal clinical trajectories.
  • Developing and applying explainable AI (XAI) techniques to GNN models.
  • Focusing on modeling and prediction of low-density lipoprotein cholesterol levels.

Main Results:

  • Initial project stages focused on methodology development.
  • Exploration of GNNs for modeling ASCVD progression.
  • Investigation into explainability of GNNs for cholesterol level prediction.

Conclusions:

  • GNNs offer a promising approach for modeling complex ASCVD progression.
  • Explainable AI (XAI) is essential for clinical adoption of GNN-based decision support.
  • Further research is needed to validate and refine these methods for clinical application.